^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    bendamustine

    i
    Other names: SDX-105, SyB L-0501
    Company:
    Generic mfg.
    Drug class:
    DNA replication inhibitor
    Related drugs:
    1d
    A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL (clinicaltrials.gov)
    P1, N=36, Active, not recruiting, Otsuka Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • bendamustine • OPB-111077
    2d
    Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant (clinicaltrials.gov)
    P1/2, N=25, Recruiting, M.D. Anderson Cancer Center | N=40 --> 25 | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
    Enrollment change • Trial completion date • Trial primary completion date • Post-transplantation
    |
    Rituxan (rituximab) • cyclophosphamide • bendamustine • melphalan • fludarabine IV • Neupogen (filgrastim)
    7d
    Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel. (PubMed, J Hematol Oncol)
    Bendamustine has been retrospectively shown to be an effective and safe lymphodepletion regimen prior to the anti-CD19 chimeric antigen receptor T cell (CART) products tisagenlecleucel and axicabtagene ciloleucel, as well as the anti-BCMA CART products idecabtagene vicleucel and ciltacabtagene autoleucel. Neutropenia ≥ grade 3 was observed in 29.0% of patients; thrombocytopenia ≥ grade 3 occurred in 9.7%. In conclusion, bendamustine lymphodepletion before liso-cel appears to be a strategy that can drive tumor responses while ensuring a mild toxicity profile.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T) • bendamustine • Abecma (idecabtagene vicleucel) • Carvykti (ciltacabtagene autoleucel)
    7d
    BRUIN CLL-321: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (clinicaltrials.gov)
    P3, N=250, Active, not recruiting, Loxo Oncology, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Rituxan (rituximab) • Zydelig (idelalisib) • Jaypirca (pirtobrutinib) • bendamustine
    18d
    Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial. (PubMed, Blood)
    The phase 2 CLL2-BAAG trial tested the measurable residual disease (MRD)-guided triple combination of acalabrutinib, venetoclax and obinutuzumab after an optional bendamustine debulking in 45 patients with relapsed/refractory CLL (one patient was excluded from the analysis due to a violation of exclusion criteria). The addition of ctDNA-based analyses to FCM MRD assessment seems to improve early detection of relapses. ClinicalTrials.gov Identifier: NCT03787264.
    Journal • Circulating tumor DNA
    |
    TP53 (Tumor protein P53) • IGH (Immunoglobulin Heavy Locus)
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Calquence (acalabrutinib) • bendamustine
    21d
    Endoscopic ultrasound-guided fine needle biopsy diagnosis of circumferentially extraluminal mucosa-associated lymphoid tissue lymphoma in the transverse colon: a case report. (PubMed, Clin J Gastroenterol)
    We performed bendamustine-rituximab (BR)-combined therapy. After six courses of BR-combined therapy, colonoscopy revealed improvement in the lead pipe sign and CT revealed disappearance of the mass.
    Journal • Biopsy
    |
    CD20 (Membrane Spanning 4-Domains A1) • BIRC3 (Baculoviral IAP repeat containing 3) • CD5 (CD5 Molecule) • MALT1 (MALT1 Paracaspase)
    |
    CD20 positive
    |
    Rituxan (rituximab) • bendamustine
    21d
    A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis (clinicaltrials.gov)
    P1, N=12, Recruiting, Stanford University | Not yet recruiting --> Recruiting
    Enrollment open • CAR T-Cell Therapy
    |
    bendamustine
    22d
    A Global Phase 3 Study of Orelabrutinib+BR vs.BR in Pts With TN MCL (clinicaltrials.gov)
    P3, N=490, Not yet recruiting, InnoCare Pharma Inc.
    New P3 trial • Combination therapy
    |
    Rituxan (rituximab) • Yinuokai (orelabrutinib) • bendamustine
    23d
    CheckMate 744: A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment (clinicaltrials.gov)
    P2, N=72, Active, not recruiting, Bristol-Myers Squibb | Trial primary completion date: Jan 2024 --> Jun 2024
    Trial primary completion date
    |
    Opdivo (nivolumab) • Adcetris (brentuximab vedotin) • bendamustine
    28d
    ZUMA-22: Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma (clinicaltrials.gov)
    P3, N=230, Recruiting, Kite, A Gilead Company | Trial completion date: Jan 2031 --> Oct 2030 | Trial primary completion date: Jan 2031 --> Oct 2030
    Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • Yescarta (axicabtagene ciloleucel) • prednisone • bendamustine • fludarabine IV
    29d
    BRUIN CLL-313: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (clinicaltrials.gov)
    P3, N=250, Active, not recruiting, Loxo Oncology, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Rituxan (rituximab) • Jaypirca (pirtobrutinib) • bendamustine
    29d
    Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=135, Active, not recruiting, National Cancer Institute (NCI)
    Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD4 (CD4 Molecule)
    |
    bortezomib • bendamustine • Arzerra (ofatumumab) • Belrapzo (bendamustine RTD)
    29d
    A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies (clinicaltrials.gov)
    P3, N=0, Withdrawn, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | N=200 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    Rituxan (rituximab) • cyclophosphamide • Zydelig (idelalisib) • Breyanzi (lisocabtagene maraleucel) • bendamustine • fludarabine IV • Belrapzo (bendamustine RTD)
    1m
    EPCORE™FL-2: Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (clinicaltrials.gov)
    P3, N=900, Recruiting, AbbVie | Trial completion date: Sep 2037 --> May 2037
    Trial completion date • Adverse events • Combination therapy
    |
    Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • Gazyva (obinutuzumab) • cyclophosphamide • vincristine • prednisone • bendamustine • Epkinly (epcoritamab-bysp)
    1m
    B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies (clinicaltrials.gov)
    P1, N=27, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting
    Enrollment open • CAR T-Cell Therapy
    |
    cyclophosphamide • bendamustine • fludarabine IV
    1m
    Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=23, Active, not recruiting, Emory University | Trial primary completion date: Sep 2023 --> Sep 2024
    Trial primary completion date
    |
    CCND1 (Cyclin D1)
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • bendamustine
    2ms
    Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=15, Terminated, Washington University School of Medicine | Trial completion date: Nov 2028 --> Mar 2024 | Active, not recruiting --> Terminated; Decision made to not move forward with Phase II portion of trial
    Trial completion date • Trial termination
    |
    bendamustine • Sarclisa (isatuximab-irfc)
    2ms
    Oracle: Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL (clinicaltrials.gov)
    P3, N=86, Active, not recruiting, The Lymphoma Academic Research Organisation | Trial completion date: Feb 2024 --> Jun 2024
    Trial completion date
    |
    PD-1 (Programmed cell death 1) • BCL6 (B-cell CLL/lymphoma 6) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • ICOS (Inducible T Cell Costimulator) • MME (Membrane Metalloendopeptidase)
    |
    PD-1 expression
    |
    gemcitabine • bendamustine • Istodax (romidepsin) • Onureg (azacitidine oral)
    2ms
    RELEVANCEt: A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma (clinicaltrials.gov)
    P3, N=1030, Active, not recruiting, The Lymphoma Academic Research Organisation | Trial completion date: Sep 2024 --> Apr 2024
    Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Rituxan (rituximab) • lenalidomide • bendamustine
    2ms
    A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma (clinicaltrials.gov)
    P3, N=300, Not yet recruiting, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
    New P3 trial
    |
    Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • Breyanzi (lisocabtagene maraleucel) • bendamustine • fludarabine IV
    2ms
    FT819 in Moderate to Severe Active Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=32, Recruiting, Fate Therapeutics
    New P1 trial
    |
    cyclophosphamide • bendamustine • fludarabine IV • FT819
    2ms
    A Rare Case of Non-IgM Lymphoplasmacytic Lymphoma with Unusual Lack of Immunoglobulin Light Chain Production. (PubMed, Am J Case Rep)
    The patient received 6 cycles of rituximab and bendamustine treatment, and no residual marrow involvement was found on the follow-up bone marrow biopsy. CONCLUSIONS We report a non-IgM LPL case featuring no light chain production and no heavy chain secretion, which we believe is the first reported case of this kind in the literature.
    Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • IGK (Immunoglobulin Kappa Locus)
    |
    MYD88 L265P • CXCR4 mutation
    |
    Rituxan (rituximab) • bendamustine
    2ms
    FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) (clinicaltrials.gov)
    P1, N=322, Recruiting, Fate Therapeutics | Trial completion date: Dec 2039 --> Jun 2044 | Trial primary completion date: Dec 2024 --> Jun 2029
    Trial completion date • Trial primary completion date • Combination therapy
    |
    cyclophosphamide • bendamustine • fludarabine IV • FT522
    2ms
    Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Fred Hutchinson Cancer Center | Initiation date: Mar 2024 --> Jul 2024
    Trial initiation date • Metastases
    |
    cyclophosphamide • bendamustine • fludarabine IV
    2ms
    GAIA: Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation (clinicaltrials.gov)
    P3, N=926, Completed, German CLL Study Group | Active, not recruiting --> Completed | Trial completion date: Feb 2025 --> Feb 2024
    Trial completion • Trial completion date • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • Gazyva (obinutuzumab) • cyclophosphamide • bendamustine • fludarabine IV
    2ms
    Anti-Cancer Effects of CDK4/6 Inhibitor LEE011 and Chemotherapy Drugs on Lymphocytic Leukemia L1210 Cells. (PubMed, Anticancer Res)
    CDK4/6 inhibitor LEE011 treatment alone may not be a suitable treatment option for lymphocytic leukemia; however, our findings in vitro support the combination of LEE011 with chemotherapy drugs to enhance anti-tumor activity in lymphocytic leukemia.
    Journal
    |
    GPX4 (Glutathione Peroxidase 4)
    |
    GPX4 expression
    |
    Kisqali (ribociclib) • bendamustine • hydroxyurea
    2ms
    Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=54, Active, not recruiting, Emory University | Trial completion date: Nov 2023 --> Dec 2024 | Trial primary completion date: Nov 2023 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • gemcitabine • bendamustine
    2ms
    B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, Mayo Clinic | Initiation date: Jan 2024 --> Jun 2024
    Trial initiation date • CAR T-Cell Therapy
    |
    cyclophosphamide • bendamustine • fludarabine IV
    2ms
    ALLIANCE A041202: Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P3, N=547, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2024 --> Jan 2025
    Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14)
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • bendamustine • Belrapzo (bendamustine RTD) • Mabtas (rituximab biosimilar)
    2ms
    MorningLyte: Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 (clinicaltrials.gov)
    P3, N=790, Not yet recruiting, The Lymphoma Academic Research Organisation
    New P3 trial
    |
    Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • Gazyva (obinutuzumab) • cyclophosphamide • prednisone • bendamustine • Lunsumio (mosunetuzumab-axgb)
    2ms
    Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=56, Active, not recruiting, Cristina Gasparetto | Trial completion date: Jan 2023 --> Jan 2025
    Trial completion date
    |
    pomalidomide • bendamustine
    3ms
    DALY 2-EU: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients (clinicaltrials.gov)
    P2, N=168, Recruiting, Miltenyi Biomedicine GmbH | Trial completion date: Dec 2024 --> Jul 2027 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD19 expression • BCL6 rearrangement • BCL2 rearrangement
    |
    gemcitabine • Rituxan (rituximab) • oxaliplatin • bendamustine • Polivy (polatuzumab vedotin-piiq) • zamtocabtagene autoleucel (MB-CART2019.1)
    3ms
    Economic Analysis of Alliance A041202 CLL Study (clinicaltrials.gov)
    P=N/A, N=55, Active, not recruiting, Canadian Cancer Trials Group | Trial completion date: Jan 2024 --> Dec 2024
    Trial completion date • HEOR
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • bendamustine
    3ms
    SHINE : A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma (clinicaltrials.gov)
    P3, N=523, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Dec 2025 --> May 2024
    Trial completion date • Combination therapy
    |
    CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • PAX5 (Paired Box 5) • CD5 (CD5 Molecule)
    |
    Chr t(11;14) • CCND1 expression
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • bendamustine
    3ms
    Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1, N=48, Active, not recruiting, Kami Maddocks, MD | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date • Combination therapy
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • bendamustine
    3ms
    Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=15, Active, not recruiting, Washington University School of Medicine | Phase classification: P1/2 --> P1 | Trial completion date: Dec 2023 --> Nov 2028
    Phase classification • Trial completion date
    |
    bendamustine • Sarclisa (isatuximab-irfc)
    3ms
    Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, Uppsala University
    New trial
    |
    bortezomib • bendamustine • melphalan
    3ms
    EPCORE™FL-2: Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (clinicaltrials.gov)
    P3, N=900, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • Gazyva (obinutuzumab) • cyclophosphamide • vincristine • bendamustine • Epkinly (epcoritamab-bysp)
    3ms
    FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=351, Recruiting, Fate Therapeutics
    New P1 trial
    |
    Erbitux (cetuximab) • cisplatin • docetaxel • cyclophosphamide • bendamustine • fludarabine IV
    3ms
    CC-95266-MM-001: A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=180, Active, not recruiting, Juno Therapeutics, a Subsidiary of Celgene | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cyclophosphamide • bendamustine • fludarabine IV • BMS-986393
    3ms
    The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P1, N=10, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Jan 2024 | Trial primary completion date: Sep 2024 --> Jan 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • bendamustine
    3ms
    Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=21, Terminated, University of Wisconsin, Madison | Trial completion date: May 2026 --> Jul 2023 | Active, not recruiting --> Terminated; slow accrual
    Trial completion date • Trial termination
    |
    CCND1 (Cyclin D1)
    |
    Gazyva (obinutuzumab) • bendamustine